A Dedicated Clinic Decreases Time From Onset of Febrile Neutropenia to Treatment
A dedicated outpatient care clinic at an established cancer center decreased the time from febrile neutropenia onset to treatment.
All articles by Jessica Nye, PhD
Poor Control of Cardiovascular Risk Factors May Be Common in Prostate Cancer
In an analysis of the RADICAL-PC study, half of prostate cancer patients had 3 or more poorly controlled cardiovascular risk factors.
New Model Better Predicts Relapse in Stage I Seminoma
A new risk stratification model can identify patients with stage I seminoma who have a high risk of relapse, according to researchers.
Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
An MMAI model can accurately predict long-term outcomes in patients with high-risk prostate cancer, a study suggests.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
Rucaparib Bests Physician’s Choice in Metastatic Castration-Resistant Prostate Cancer
Rucaparib improves radiographic progression-free survival when compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer, according to results from the TRITON3 trial.
TALAPRO-2: Talazoparib Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
Adding talazoparib to first-line treatment with enzalutamide improves radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, results of the TALAPRO-2 trial suggest.
AAP and Apalutamide May Improve Outcomes in Subgroup of Prostate Cancer Patients
AAP and apalutamide may improve outcomes, compared with bicalutamide, in a subgroup of patients with prostate cancer receiving ADT and salvage radiation after radical prostatectomy, according to researchers.
Nurse-Parent Collaboration Key to Successful 131I-MIBG Treatment for Neuroblastoma
Collaboration between parents and nurses is essential to the care of children with neuroblastoma receiving 131I-MIBG, a study suggests.
- Loading...
Loading...
Next post in Endocrine Cancer
Loading... 
Loading...